Quick Highlights:
- BioNTech reports first-quarter financial loss, yet affirms 2025 revenue targets.
- Average analyst price target for BNTX is $137.14, suggesting a 30.69% upside.
- GuruFocus estimates indicate a significant downside, valuing BNTX at $24.56.
BioNTech SE (BNTX, Financial) recently announced its first-quarter earnings, posting a GAAP EPS of -€1.73 as their revenue saw a 2.6% decline year-over-year, settling at €182.8 million. Despite this setback, the company is holding steady to its optimistic financial outlook through 2025, forecasting revenues in the range of €1,700 million to €2,200 million.
Wall Street Analysts Forecast
According to insights from 19 analysts, BioNTech SE's (BNTX, Financial) average one-year price target is set at $137.14. This reflects potential high estimates of $171.05 and low projections of $110.03, implying a promising upside of 30.69% from the current trading price of $104.94. Investors and interested parties can further explore these projections on the BioNTech SE (BNTX) Forecast page.
Furthermore, an analysis of 21 brokerage firms offers an average recommendation rating of 2.0 for BioNTech SE (BNTX, Financial), which corresponds to an "Outperform" status. This consensus falls on a rating scale where 1 indicates a Strong Buy, and 5 indicates a Sell.
GuruFocus Valuation Insights
The GF Value metric by GuruFocus presents a contrasting view, estimating BioNTech SE (BNTX, Financial)'s value at $24.56 over the next year. This assessment suggests a dramatic downside of 76.6% from its current price of $104.94. The GF Value is computed by taking into account the historical trading multiples of the stock, past growth, and future business performance estimates. For more detailed valuation metrics and data, visit the BioNTech SE (BNTX) Summary page.
